Sichenzia Ross Friedman Ference LLP Represents DelMar Pharmaceuticals, Inc. in $7.5 Million Sale of Series B Preferred Shares
Press Release – New York, NY – May 5, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm represented DelMar Pharmaceuticals, Inc. in connection with the sale of $7,500,000 of its Series B Preferred Shares. DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments.
The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia and David Manno and associate Jeff Cahlon.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)